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The Mannose Receptor
Delivers Lipoglycan Antigens to Endosomes
for Presentation to T Cells by CD1b Molecules
Theodore I. Prigozy,1 Peter A. Sieling,2 motif in their cytoplasmic tail that is similar to the endo-
somal targeting signals of lysosomal glycoprotein A andDaniel Clemens,3 Phoebe L. Stewart,5, 6, 7
Samuel M. Behar,8 Steven A. Porcelli,8 CD63 (Sandoval and Bakke, 1994). Sugita et al. (1996)
have established that the cytoplasmic tail of CD1b is aMichael B. Brenner,8 Robert L. Modlin,1, 2, 7
and Mitchell Kronenberg1, 4, 7 signal that targets CD1b to late endosomes and major
histocompatibility complex (MHC) class II compart-1Department of Microbiology and Immunology
2Division of Dermatology ments (MIICs), possibly via internalization from the
plasma membrane.3Division of Infectious Diseases
4Division of Digestive Diseases The macrophage mannose receptor (MR) is a C-type
lectin expressed primarily by macrophages and den-Department of Medicine
5Department of Molecular and Medical Pharmacology dritic cells, as well as endothelial cells (Ezekowitz et al.,
1990; Taylor et al., 1990). Recently, the MR and a related6Crump Institute for Biological Imaging
7Molecular Biology Institute mouse protein, DEC-205 (Jiang et al., 1995), have been
implicated as potential antigen capture molecules withUniversity of California at Los Angeles
Los Angeles, California 90095 the capability of directing the transport of ligands into
endosomal compartments (Sallusto et al., 1995). Neither8Division of Rheumatology and Immunology
Department of Medicine cell surface protein, however, has been linked to the
uptake of antigens that are ultimately presented to TBrigham and Women’s Hospital
Boston, Massachusetts 02115 cells during an immune response to an infectious agent.
In addition, the mechanismby whichlipoglycan antigens
are transported to antigen-presenting compartments
has not been explored. Because of the ability of the MR
Summary to bind LAM (Schlesinger et al., 1994; Venisse et al.,
1995) and other pathogen-associated polymannose
We have characterized the CD1b-mediated presenta- structures (O’Riordan et al., 1995; Cross and Bancroft,
tion pathway for the mycobacterial lipoglycan lipoara- 1995), we considered it to be a candidate molecule for
binomannan (LAM) in monocyte-derived antigen-pres- mediating the internalization of LAM into endosomal
enting cells. The macrophage mannose receptor (MR) compartments for presentation to LAM-specific T cells.
was responsible for uptake of LAM. Antagonism of MR The goal of this study, therefore, was to define the
function inhibited both the internalization of LAM and CD1b-mediated antigen presentation pathway for LAM,
the presentation of this antigen to LAM-reactive T including the mechanism of LAM uptake, the fate of
cells. Intracellular MRs were most abundant in early LAM in the endocytic pathway, and the likely site of
endosomes, but they also were located in the com- encounter of LAM with CD1b in antigen-processing
partment for MHC class II antigen loading (MIIC). In- compartments. These data outline a novel nonpeptide
ternalized LAM was transported to late endosomes, antigen presentation pathway that links pattern recogni-
lysosomes, and MIICs. MRs colocalized with CD1b tion molecules involved in “first line defense” to adap-
molecules, suggesting that the MR could deliver LAM tive, T cell–mediated immune responses.
to late endosomes for loading onto CD1b. LAM and
CD1b colocalized in organelles that may be sites of
Resultslipoglycan antigen loading. This pathway links recog-
nition of microbial antigens by a receptor of the innate
MR Function Is Required for the Presentationimmune system to the induction of adaptive T cell
of LAM to T Cellsresponses.
The involvement of the MR in the uptake of LAM by
CD11 antigen-presenting cells (APC) was established
by testing theability of theMR ligand a-mannan to inhibitIntroduction
the antigen-dependent proliferation of the LAM-specific
T cell line LDN4 (Sieling et al., 1995). In this experimentalThe CD1 proteins are nonpolymorphic, b2m-associated
cell surface glycoproteins that have been shown to have system, APC for the LDN4 T cells are derived by treat-
ment of peripheral blood mononuclear cells with granu-antigen presentation function (Calabi and Bradbury,
1991; Porcelli, 1995; Porcelli and Modlin, 1995). Human locyte/macrophage colony-stimulating factor (GM-CSF)
and interleukin-4 (IL-4) (Porcelli et al., 1992). The re-CD1b presents nonpeptide components of mycobact-
eria, including the lipid mycolic acid and the lipoglycan sulting population of APC consists of dendritic cells and
macrophages, of which greater than 50% are CD1b/MRlipoarabinomannan (LAM), to double negative T cells.
The sensitivity of the antigen presentation of both my- double positive (data not shown). For consistency, the
cells from this primary culture are referred to simply ascolic acid (Porcelli et al., 1992; Beckman et al., 1994)
and LAM (Sieling et al., 1995) to agents that inhibit endo- APC throughout. The APC were incubated with LAM in
the presence of LDN4 cells and increasing concentra-somal acidification suggests a CD1-mediated presenta-
tion pathway for nonpeptide antigens that involves en- tions of either mannan or mannose, which does not bind
the MR, as a control ligand. T cell proliferation wasdosomes. Human CD1b molecules contain a sequence
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1B). The inhibition of antigen presentation by the anti-
MR antiserum was observed only when the antiserum
was added prior to the addition of LAM. In contrast,
when the APC were pulsed with LAM for 2 hr prior to
the addition of the blocking antiserum, no inhibition was
observed. Because the MR antiserum must be added
prior to LAM to inhibit the T cell response, we conclude
that the antibodies most likely are blocking LAM uptake.
Blockade of MR Function Inhibits
the Internalization of LAM
To test the hypothesis that the MR was indeed function-
ing as the receptor for the uptake of LAM in these APC,
we used quantitative immunoelectron microscopy to
measure the amount of LAM that was internalized in the
presence and absence of mannan. APC were pulsed
with LAM for 3 hr with and without mannan. After fixation,
sections were stained for both LAM and the late endoso-
mal marker CD63. The amount of LAM-specific immuno-
gold was quantitated by counting gold particles per
square micron of cytoplasm in electron micrographs of
20 consecutive cells. LAM uptake was inhibited approxi-
mately 4-fold by mannan (0.14 gold particles/mm2) rela-
tive to the untreated control cells (0.62 gold particles/
mm2). The levels and distribution of CD63 in late endo-
somes were not altered by the mannan treatment (data
not shown). This established the MR as the principal
receptor for LAM uptake into endocytic vesicles.
The MR Is Present Predominantly
in Early Endosomes
We investigated the distribution of MR in APC to deter-
mine whether the MR might transport LAM to late endo-
somal compartments known to contain CD1b (Sugita et
al., 1996). As the cytoplasmic tail of the MR containsFigure 1. The MR Is Required for Presentation of LAM
signals required for its internalization from the plasma(A) Inhibition of LDN4 proliferation by the MR ligand mannan. CD11
membrane (Ezekowitz et al., 1990), we therefore ex-APC were incubated with Mycobacterium leprae LAM (1 mg/ml) and
pected to find the MR in early endosomes. Cells wereincreasing concentrations of mannose (open squares) or mannan
(closed squares), followed by the addition of LDN4 (1 3 104) T cells fluorescently labeled for various times with dextran–
for 3 days. The resulting T cell proliferation data were plotted as Texas red to trace the trafficking of an internalized anti-
percent inhibition versus the concentration of the ligand. Data from gen along the endocytic pathway. The majority of the
three independent experiments gave similar results.
MR colocalized with dextran after 15 min (Figure 2A),(B) Anti-MR antiserum inhibits IFNg production by LDN4. CD11 APC
indicating that the MR was most abundant in early endo-were subjected to the following protocols, as indicated in the figure
somes. The MR colocalized only to a limited extent withand described in Experimental Procedures: LAM, APC incubated
with LAM for 2.5 hr followed by two washes with media; no antigen, dextran in perinuclear vesicles after 2 hr (Figure 2B),
APC incubated for 2.5 hr without LAM followed by two washes with establishing that a minority of the MR molecules are
media; anti-MR followed by LAM, APC were incubated with an anti- resident in late endosomes. APC were incubated for 1 hr
MR antiserum (1:300) for 60 min, and after one wash with media,
with dextran followed by an overnight chase to labelLAM was added for 2.5 hr followed by two washes with media;
mature late endosomal compartments such as lyso-preimmune followed by LAM, same as above except for the addition
somes and MIICs. There was a moderate amount ofof preimmune goat serum rather than the anti-MR antiserum; LAM
followed by anti-MR, LAM was added to the APC for 2 hr followed colocalization of the MR and dextran (Figure 2C), which
by one wash with media. The anti-MR antiserum was added for 1.5 was in general greater than that observed in the 2 hr
hr followed by two washes with media. LDN4 cells (5 3 104) were labeling. These data suggest that, although a significant
added to the washed APC, and IFNg production was measured after
fraction of the MR is not resident in classical late endo-36 hr by ELISA. Data from three different experiments gave similar
somes (Figure 2B), the MR can be detected in matureresults.
endosomal compartments, which could include lyso-
somes and the MIIC.
The types of endosomal compartments expressinginhibited in a dose-dependent fashion by mannan, but
not mannose (Figure 1A). Similarly, pretreatment of the MR were further characterized by confocal imaging
of APC labeled for both MR and proteins specific forthese APC with either mannan (data not shown) or a
polyclonal antiserum raised to theMR significantly inhib- different types of endosomes. The MR and the trans-
ferrin receptor (TfnR), a marker for early endosomes,ited interferon-g (IFNg) production by LDN4 cells (Figure
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Figure 2. The MR Is Present in Early and Late
Endosomal Compartments
(A–C) MR colocalization with internalized de-
xtran. Prior to fixation, the APC were labeled
with the MR ligand dextran–Texas red for 15
min (A), 2 hr (B), or 1 hr with an overnight
incubation (C). The fluorescently labeled APC
were analyzed with a confocal laser scanning
microscope (CLSM, Leica). Optical slices (0.5
mm) were scanned for FITC and Texas red
fluorescence. The images are displayed in
three panels with green (MR detected by
FITC), red (dextran detected by Texas red),
and yellow signal (depicting colocalization).
(D) MR colocalizes with the clathrin adaptor
protein, a-adaptin. MR proteins were de-
tected with Texas red (red). a-Adaptin was
detected with FITC (green).
(E) MR colocalizes with the late endosomal
protein CD63. MR, red; CD63, green. Colocal-
ization was represented by yellow signal.
(F–G) Detection of MR in early endosomes
and MIICs by immunoelectron microscopy.
APC were processed for immunogold label-
ing as described in the text. The sizes of the
gold particles used for the detection of each
proteinare shown in the corner of eachmicro-
graph. In (F), MRs and TfnRs colocalize in
early endosomes and on the plasma mem-
brane. The scale bar is 100 nm. In (G), MRs
are found in the MIIC with HLA-DR molecules.
The locations of the MR-specific immunogold
particles are indicated by the arrowheads.
The scale bar is 100 nm.
colocalized extensively in peripheral vesicles or early there was colocalization of the MR and a-adaptin in
vesicles near the cell surface and in more centrally lo-endosomes (data not shown), consistent with the results
from the 15 min dextran labeling (Figure 2A). In addition, cated vesicles (Figure 2D). a-Adaptin is present in both
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coated vesicles derived from the cell surface and recy- 3). After a 3 hr antigen pulse, LAM colocalized exten-
sively with the late endosomal/lysosomal markers CD63cling vesicles derived from the trans-Golgi apparatus
(Chin et al., 1989). The colocalization of MR with (Figure 3A) and cathepsin D (Figure 3B) in perinuclear
electron-dense compartments that are 150–200 nM ina-adaptin suggests that the MR might recycle from the
plasma membrane via clathrin-coated vesicles. To con- diameter. LAM also was observed in CD63-positive
compartments with the multilamellar morphology char-firm the presence of the MR in late endosomal/lyso-
somal compartments, clearly observed following an acteristic of MIICs (Figure 3C). In addition, LAM and
CD63 also colocalized in very large (.500 nm diameter),overnight chasewith dextran (Figure 2C), we colocalized
the MR with the late endosomal protein CD63. Signifi- electron-dense multivesicular structures (Figure 3D).
The large size and internal vesicular morphology wascant colocalization was observed in perinuclear vesicles
(Figure 2E). similar to that of mouse dendritic cell MIICs previously
described (Kleijmeer et al., 1995). In summary, after 3 hr
the majorityof LAM was transported to typical late endo-The MR Is Also Found in the MIIC
somal compartments, while a smaller fraction of theTo determine the ultrastructure of compartments ex-
internalized LAM was present in larger compartmentspressing the MR, we used immunoelectron microscopy
that were either MIICs or lysosomes.to colocalize the MR with proteins specific to early and
late endosomal compartments. The MR colocalized with
TfnR in small vesicles (100 nm diameter) of low electron The Transport of LAM to Late Endosomes
Requires Endosome Acidificationdensity (Figure 2F). In two independent experiments,
most of the MR-specific immunogold particles were Lysomotropic agents, such as the proton pump antago-
nist concanamycin A, are potent inhibitors of LAM pre-present either in vesicles expressing the TfnR or on the
plasma membrane (data not shown). This confirms the sentation to T cells (Sieling et al., 1995). To test whether
this inhibition was related toa decrease inLAM transportdata from the confocal microscopy experiments (Figure
2A), which indicated that most of the intracellular MR to late endosomes, we used immunoelectron micros-
copy to quantitate the impact of concanamycin A on themolecules are in early endosomes.
Specialized vesicles for loading peptides into class II arrival of LAM to compartments expressing cathepsin D
and CD63. LAM immunogold particles that were presentmolecules have been defined recently, variously called
MIIC or CIIV (Peters et al., 1991, 1995; Harding and in vesicles containing CD63 or cathepsin D were
counted in cells treated with the inhibitor and controlGeuze, 1992; Amigorena et al., 1994; West et al., 1994;
Pierre et al., 1996). Those called MIIC generally were cells. Although LAM uptake was not affected by the
concanamycin A treatment (data not shown),LAM trans-originally defined on the basis of their multilamellar or
multivesicular character (Peters et al., 1991; Sanderson port to late endosomes was inhibited 5-fold in theconca-
namycin A–treated cells (Figure 3E). This correlated theet al., 1994; Tulp et al., 1994), and they are CD63-posi-
tive, electron-dense vesicles with some features in com- transport of LAM to late endosomes with its presentation
to T cells by CD1b.mon with lysosomes (Kleijmeer et al., 1995; Peters et
al., 1995). The MR was detected in large multilamellar
compartments expressing the MHC class II molecule CD1b Molecules Localize Primarily
HLA-DR (Figure 2G). Of 65 multilamellar compartments in Late Endosomes
with the morphology of the organelle in Figure 2G, 61 To define the compartments where CD1b molecules en-
(94%) had two or more HLA-DR immunogold particles counter lipoglycan antigens taken up by the MR, we
and 34 (52%) had two or more MR immunogold particles. used confocal microscopy to define the distribution of
These compartments were usually CD63 positive. Of 40 CD1b in APC that were treated with the MR ligand dex-
compartments that were analyzed, 38 (95%) had two or tran–Texas red for varying periods of time (Figure 4).
more CD63 immunogold particles. The MR also coloca- CD1b and dextran did not colocalize extensively when
lized in large multilamellar compartments with another APC were labeled with dextran–Texas red for 15 min
molecule found in the MIIC (Peters et al., 1995), cathep- (Figure 4A). In contrast, following a 2 hr incubation, dex-
sin D (data not shown). In contrast, the MR and HLA-DR tran and CD1b colocalized to a great extent in perinu-
were found in less than 5% of the latex bead–containing clear and peripheral vesicles (Figure 4B). CD1b coloca-
phagosomes in these same cells (data not shown). lized most extensively with dextran that had been
Phagosomes were labeled by incubating the APC for allowed to progress to more terminal late endosomal
1 hr with latex beads followed by an overnight chase. compartments such as lysosomes and MIICs following
The morphology of the late endosomal MR-positive a 1 hr incubation and overnight chase (Figure 4C).
compartments (Figure 2G), their staining for HLA-DR, To define more precisely the intracellular distribution
and the presence of other markers characteristic of late of CD1b molecules, we used confocal microscopy to
endosomes/lysosomes identified these vesicles as MI- colocalize CD1b with markers for endosomal compart-
ICs. In summary, at steady-state the majority of the MRs ments, as described above for the MR. Consistent with
are present in early endosomes, with a smaller fraction the dextran labeling results, CD1b colocalized to only a
present in MIICs. minor extent in early endosomes with the TfnR (Figure
4D). There was some colocalization with a-adaptin (Fig-
ure 4E), suggesting that some CD1bmolecules can recy-LAM Is Transported to Late Endosomes
We used immunoelectron microscopy to examine the cle from the plasma membrane in clathrin-coated pits.
There was much more extensive colocalization of CD1bintracellular fate of LAM internalized by the MR (Figure
Lipoglycan Antigen Presentation Pathway
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Figure 3. LAM Is Transported to Late Endosomes
APC were pulsed with LAM for 3 hr and analyzed by immunoelectron
microscopy. The sizes of the gold particles used for the detection of
LAM and the late endosomal markers are indicated on each micrograph.
(A) LAM colocalizes with the late endosomal marker CD63. The scale
bar is 200 nm.
(B) LAM colocalizes with the late endosomal/lysosomal marker cathep-
sin D. The scale bar is 200 nm.
(C) LAM and CD63 colocalize in MIIC-like structures. The scale bar is
100 nm.
(D) LAM and CD63 colocalize in large multivesicular structures. The
scale bar is 200 nm.
(E) Concanamycin A inhibits the transport of LAM to late endosomes.
The cells were prepared as described in Experimental Procedures ex-
cept for the addition of 10 nM concanamycin A to one flask while a
second flask served as the control. The colocalization of LAM with the
indicated markers was quantitated by counting the number of LAM-
positive vesicles that were also immunogold positive for either cathep-
sin D or CD63 in the control and concanamycin A–treated cells. The
data shown represent counts made from two independent immunogold
labelingexperiments. In each case, at least 100 LAM-containing vesicles
were counted with minor variation between the two labelings. See text
for details.
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with CD63, particularly in perinuclear compartments
(Figure 4F).This is consistent with theextensive colocali-
zation of CD1b with labeled dextran following an over-
night chase (Figure 4C).
We used immunoelectron microscopy to determine
whether CD1b was present in lysosomes. APC that were
loaded with latex beads were analyzed by immunoelec-
tron microscopy after an overnight incubation (Figure
4G). CD1b molecules were present on the plasma mem-
brane and in latex bead–labeled lysosomes. This dem-
onstrated that CD1b trafficked tophagolysosomes, pos-
sibly via internalization from the cell surface. The
significant colocalization of CD1b with both CD63 and
dextran following an overnight chase, and the observa-
tion that CD1b colocalizes with phagocytosed latex
beads, demonstrated that the majority of the intracellu-
lar CD1b molecules were present in mature late endo-
cytic compartments, such as lysosomes and MIICs, with
only a minority resident in early endosomes.
Colocalization of CD1b with MHC
Class II Molecules
To begin to determine whether CD1b molecules might
be found in MIICs, as reported previously using slightly
different culture conditions (Sugita et al., 1996), we de-
termined the intracellular distribution of CD1b and HLA-
DR. There was colocalization of CD1b and HLA-DR (Fig-
ure 5A) in internal vesicles. As the majorityof intracellular
HLA-DR molecules are in the MIIC (Peters et al., 1995),
this is consistent with the reported cytoplasmic tail–
dependent localization of CD1b molecules to these spe-
cialized compartments (Sugita et al., 1996). The majority
of the APC analyzed characteristically had high levels
of intracellular CD1b, while the majority of the HLA-DR
was on the cell surface. This suggests that the kinetics
of the pathway of CD1b trafficking is different from HLA-
DR despite the presence of both antigen-presenting
molecules in overlapping compartments. In contrast
with the data for class II molecules, there was minimal
intracellular colocalization of CD1b with MHC class I
molecules (Figure 5B). MHC class I molecules coloca-
lized with CD1b primarily on the cell surface (Figure 5B).
Class I molecules were also detected in intracellular
vesicles, which may correspond to sorting vesicles de-
rived from the trans-Golgi network (Figure 5B). In conclu-
sion, despite their association with b2m, CD1b mole-
cules colocalize extensively with HLA-DR molecules in
vesicular compartments.
red (red). The colocalization of CD1b with dextran is indicated by
yellow signal. The APC were labeled with dextran–Texas red for 15
min (A), 2 hr (B), and 1 hr followed by an overnight incubation (C).
CD1b molecules (red) were colocalized with the following organelle-
specific proteins: TfnR (D; green), a-adaptin (E; green), and CD63
(F; green). CD1b is present in phagolysosomes (G). The presence
of CD1b in lysosomes was demonstrated by labeling lysosomes
with phagocytosed latex beads. CD1b gold (10 nm) colocalized in
Figure 4. CD1b Is Present in a Variety of Endocytic Compartments
lysosomes with latex beads (bead [B]). The locations of the CD1b
CD1b was colocalized with internalized dextran–Texas red and en- gold particles (arrows) and the plasma membrane (p) are indicated.
dosome-specific proteins in APC by confocal microscopy as de- Counting immunogold particles of CD1b revealed that 25% of latex
scribed in Experimental Procedures. Optical slices (0.5 mm) were bead phagosomes stained positive for CD1b immunogold particles
displayed as three panel images. CD1b was detected with FITC- as compared with 0% for control antibody gold particles. Vesicles
conjugated antibodies (green),and dextran was conjugatedto Texas were scored as positive if they contained three or more CD1b immu-
nogold particles. The scale bar is 200 nm.
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Figure 5. Intracellular CD1b and MHC Class
II Molecules Colocalize Extensively
Immunofluorescently labeled APC were ana-
lyzed by confocal microscopy as described
in Experimental Procedures.
(A) CD1b molecules (red) were colocalized
with HLA-DR molecules (green).
(B) CD1b molecules (green) were colocalized
with MHC class I molecules (red). The colo-
calization is represented by yellow signal.
CD1b Colocalizes with the MR in the MIIC CD1b, where the interaction of CD1b with LAM or pro-
cessed fragments of LAM might occur.The colocalization of the MR and CD1b with markers
of the endosomal pathway suggested an overlapping
distribution for these two polypeptides, although the MR Discussion
was found predominantly in early endosomes with CD1b
mostly in late endosomes. A possible colocalization of We have established that the major pathway for CD1b-
mediated presentation of the lipoglycan LAM in mono-the MR and CD1b was of interest, because it would
suggest that the MR might directly transport LAM to cyte-derived APC is initiated by the MR. The data are
consistent with a model in which LAM is internalized viacompartments where it could interact with CD1b. We
investigated the possibility that the MR and CD1b may the MR into early endosomes and subsequently trafficks
into late endosomal/lysosomal compartments and MIICsbe coexpressed in a subset of endosomes. Double im-
munofluorescently labeled APC were analyzed by con- where it most likely encounters CD1b. An outline of this
model is presented in Figure 7. In the cytokine-derivedfocal imaging (Figure 6A). CD1b and the MR colocalized
in vesicles that were in the perinuclear region, which APC, blockade of the MR inhibited both LAM uptake and
LAM presentation, implicating the MR as the principlewere probably late endosomal compartments. The ma-
jority of the APC that were analyzed contained a large molecule for capture of this antigen (Figure7). The block-
ade was substantial but was never complete, and thenumber of vesicles that expressed both CD1b and MR
(data not shown). We characterized the types of com- data therefore do not rule out the existence of a relatively
minor, MR-independent pathway for uptake of LAM inpartments that expressed both MR and CD1b using im-
munoelectron microscopy. MR and CD1b colocalized the APC. The MR, like other endocytic receptors such
as GLUT-4 (Chakrabarti et al., 1994), was most abundantin multilamellar organelles which, based on their mor-
phology, were most likely MIICs (Figure 6B). in early endosomes at steady-state. This was evidenced
by the colocalization of the MR with the TfnR, a-adaptin,
and newly internalized dextran. On this basis, we con-CD1b and LAM Colocalize in Late Endosomes
To identify the compartments where CD1b molecules clude that the MR transports LAM to early endosomes.
The MRis known to release some ligands at mildly acidicmight encounter lipoglycan antigens, we colocalized
LAM and CD1b in APC by immunoelectron microscopy. pH (Diaz et al., 1989), raising the possibility that LAM
might dissociate from the MR in early endosomes andLAM and CD1b could be colocalized in several types of
late endosomal/lysosomal structures; in general, CD1b that LAM subsequently trafficks to late endosomes un-
bound from the MR as depicted in Figure 7. The require-localized to membranes of the various compartments
(Figures 6C and 6D). One of these structures is a large ment for lipoglycan antigen transport to late endosomes
was suggested by the inhibition of both LAM transport(.500 nm diameter) multilamellar, electron-dense vesi-
cle (Figure 6C) similar to the LAM-containing CD63-posi- and antigen presentation (Sieling et al., 1995) by antago-
nism of the vacuolar-H1 ATPase. This treatment, how-tive compartment shown in Figure 2D. The morphology
and the presence of CD63 suggest that one of the com- ever, did not inhibit LAM uptake to early endosomes,
demonstrating that the uptake of LAM into early endo-partments for LAM–CD1b interaction may be a lysosome
or an MIIC. The multilamellar character suggests that it somes is not sufficient for effective antigenpresentation.
It remains possible, however, that the effect of concana-could be an MIIC. Consistent with this, HLA-DR mole-
cules also could be detected in this type of compartment mycin A is primarily due to its inhibition of acidification,
which might prevent lipoglycan dissociation from the(data not shown). LAM and CD1b were also detected in
smaller electron-dense organelles, some of which were MR (Diaz et al., 1989), rather than to inhibition of trans-
port to late endosomes. It is noteworthy that althoughmultilamellar (Figure 6D). In summary, LAM is trans-
ported to late endosomal compartments containing the MR was not broadly distributed in late endosomes
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Figure 6. CD1b Colocalizes with LAM and MR in Late Endosomal
Compartments
LAM and CD1b were colocalized by immunoelectron microscopy
as described in Experimental Procedures.
(A) MR and CD1b colocalize in perinuclear compartments. APC were
double labeled for MR (red) and CD1b (green). The fluorescently
labeled APC were scanned using the 633 objective and the colocali-
zation was represented by yellow signal.
(B) MR and CD1b colocalize in MIICs. The compartments where MR
and CD1b colocalized were determined by immunoelectron micros-
copy as described in the text. The locations of the MR-specific
immunogold particles are indicated by the arrowheads. The scale
bar is 200 nm, and the sizes of the immunogold particles are indi-
cated on the micrograph.
(C) LAM colocalizes with CD1b in electron-dense late endosomal
compartments. The electron-dense vesicle may have been fusing
with a lysosome (L). The sizes of the gold particles used for detection
of LAM (arrows) and CD1b (arrowheads) are shown on the micro-
graph, and the scale bar is 200 nm.
(D) LAM and CD1b colocalize in late endosomal compartments.
The locations of the LAM-specific and CD1b-specific immunogold
particles are indicated by arrows and arrowheads, respectively. The
scale bar is 100 nm.
and lysosomes, a significant fraction of the MR was CD1b can all be colocalized to the MIIC and that the
MIIC is the major late endosomal compartment wherepresent in MIICs. As the pH sensitivity of the LAM–MR
interaction has not been determined, the LAM–MR inter- the MR can be localized. This reinforces the hypothesis
(Sugita et al., 1996) that both peptide antigen and lipog-action might be able to survive the more acidic pH of
late endosomes and the MIIC. The localization of the lycan antigen binding occur in the same specialized
endosomes. It remains formally possible, however, thatMR in the MIIC therefore raises the possibility that the
MR and LAM might remain bound and that the MR might some LAM molecules encounter CD1b in early endo-
somes. There was colocalization of CD1b with the TfnR,transport LAM and other ligands directly to compart-
ments where antigens are loaded onto CD1b, which is although the majority of intracellular CD1b molecules
clearly are not in early endosomes.shown as an alternative pathway in Figure 7.
The model presented depicts a most likely account In this report, an MR-mediated pathway for uptake of
extracellular LAM has been defined. What might be theof the site(s) where CD1b binds lipoglycan antigen. The
steady-state analysis we have carried out shows that the physiological significance of this pathway in the context
of mycobacterial infection? In natural infections, Myco-great majority of CD1b is localized to a set of vesicular
structures that includes late endosomes, MIICs, and bacterium tuberculosis can multiply either intracellularly
within host mononuclear cells or extracellularly in lunglysosomes, implicating one or more of these compart-
ments as the primary site for CD1b–antigen interactions. cavities. The pathway of LAM endocytosis, processing,
and presentation studied here therefore is relevant bothThe data presented do not specify which of these sites
is most important. It is intriguing that the MR, LAM, and to LAM shed by extracellular mycobacteria multiplying
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Figure 7. A Model of LAM and CD1b Traffick-
ing through the Endosomal Compartments
of APC
Six steps in what is likely to be the major
pathway for LAM presentation are illustrated
including the following: 1, binding of LAM to
the MR; 2, internalization of the LAM–MR
complex to early endosomes; 3, release of
LAM from the MR into the acidic environment
of the endosome; 4, traffic of LAM to late en-
dosomes/MIICs/lysosomes; 49, alternatively,
traffic of the LAM–MR complex to late endo-
somal sites for antigen binding to CD1b; 5 or
59, binding of LAM to CD1b in these compart-
ments; 6, traffic of the LAM–CD1b complex
to the cell surface.
al., 1992). High pressure liquid chromatography–purified prepara-in lung cavities and to LAM released into theextracellular
tions that were greater than 95% pure were used for all studiesmedium from infected mononuclear phagocytes. LAM
(provided by Dr. D. Chatterjee and Dr. P. Brennan, Colorado Statethat is shed directly into the mycobacterial phagosome
University).
of infected mononuclear phagocytes may not be imme-
diately available for antigen processing within the Preparation of APC
phagosome because the mycobacterial phagosome re- APC that were MR/CD1b positive were derived by GM-CSF and IL-4
treatment of human peripheral blood mononuclear cells (PBMC)sists acidification (Crowle et al., 1991) and shows a re-
(Porcelli et al., 1992). The PBMC were treated with GM-CSF (400stricted acquisition of lysosomal hydrolases (Clemens
U/ml) and IL-4 (200 U/ml) for 6 days at a cell density of 5 3 106 cellsand Horwitz, 1995). LAM shed by mycobacteria into the
per milliliter in the presence of 10% fetal calf serum (Hyclone, Logan,
phagosome may reachthe endocytic pathway, however, UT). This population consisted of monocytes, macrophages, and
either by intracellular trafficking (not likely to be MR dendritic cells as evidenced by flow cytometric analysis of CD14,
dependent given the sparse MR concentration in the CD1b, class II MHC, and CD83 expression (data not shown).
phagosome) or by release into the extracellular medium
Antigen Presentation Assaysand reuptake, which we believe is mostly MR depen-
For T cell proliferation, 1 3 105 APC and 1 3 104 LDN4 T cells specificdent. Consistent with these possibilities, Xu et al. (1994)
for M. leprae LAM were used in the assays. In triplicates, APC were
have previously reported the presence of LAM in vesi- preincubated with increasing concentrations (0, 0.01, 0.1, 1, and 10
cles outside of the M. tuberculosis phagosome. Since mg/ml) of mannan or mannose for 30 min prior to the addition of M.
mycobacteria-reactive and CD1b-restricted T cells se- leprae LAM (1 mg/ml) and the LDN4 cells. After 3 days, the cells
were pulsed with [3H]thymidine for 4 hr as described previouslycrete proinflammatory cytokines and are cytotoxic
(Sieling et al., 1995), and the incorporated thymidine was measured(Beckman et al., 1994; Sieling et al., 1995), LAM-reactive
by scintillation counting. Similar results were obtained in three inde-cells induced by the pathway described here could have
pendent experiments. For IFNg production, 4 3 105 APC were incu-
an important effector role in cell-mediated immunity to bated with either preimmune goat serum, an anti-MR antiserum
mycobacteria. (provided by Dr. P. Stahl, Washington University, St. Louis, MO), or
MR-binding lipoglycans and glycoproteins are pres- media alone for 30 min. The cells were washed and then incubated
with M. leprae LAM for 2.5 hr. Alternatively, APC were preincubatedent in a variety of bacterial and fungal pathogens. It is
with LAM for 2 hr prior to the addition of the antibodies. The cellstherefore unlikely that the CD1b antigen uptake and
were washed and incubated with the T cells (4 3 104) for an additionalpresentation system outlined here evolved solely to
36 hr. The culture supernatants were assayed for IFNg, in triplicates,
combat mycobacterial infections. We speculate that the by capture ELISA (enzyme-linked immunosorbent assay) using two
MR may help survey the extracellular environment by anti-IFNg antibodies (Endogen, Woburn, MA). 96-well plates were
binding polymannose ligands and initiating or directing coated with capture antibody, blocked, and incubated with IFNg
standards and the culture supernatants. The captured IFNg wastheir transport tospecialized endosomes. Therefore, the
detected with a biotinylated anti-IFNg detection antibody followedpathway of MR-mediated uptake leading to antigen pre-
by streptavidin-peroxidase (Sigma Chemical Co., St. Louis, MO) andsentation by CD1b could be important in the immune
the chromogenic peroxidase substrate. The absorbance at 405 nm
response to a variety of pathogens. This pathway links was measured with an ELISA plate reader, and the IFNg concentra-
the innate immune response, namely pattern recognition tions were determined from the standard curve. Similar results were
receptors expressed by macrophages and dendritic obtained in three independent experiments.
cells, to the adaptive immune response, in this case
Immunofluorescent Detection of CD1b and the MRthe activation of CD1b-restricted T cells. Such linkages
APC were plated in 8-well permanox chamber slides at a densitybetween the innate and adaptive immune responses
of 1 3 105 cells per well. After overnight adherence, CD1b molecules
could be a general feature of the induction of cell-medi- were immunofluorescently localized in formaldehyde-fixed APC that
ated immunity. were permeabilized with 0.1% saponin in PBS for 15 min. Prior to
the addition of the primary antibodies, the cells were incubated with
10% rabbit serum in PBS containing 0.025% saponin. We includedExperimental Procedures
2% rabbit serum and 0.025% saponin in all subsequent antibody
incubations. CD1b molecules were detected with one of two mono-Antigens
LAM derived from Mycobacterium leprae and M. tuberculosis was clonal antibodies (Serotec, Washington, D.C.). All of the fluoro-
chrome-conjugated secondary antibodies used in this study wereprepared according to well-established procedures (Chatterjee et
Immunity
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F(ab9)2 fragments (Jackson Immunoresearch, West Grove, PA). Two anti–goat IgG gold-conjugated antibodies (Jackson Immunore-
search). The immunogold-labeled sections were viewed with a JEOLdouble labeling protocols were used to colocalize CD1b with organ-
elle-specific proteins. For colocalization of CD1b with TfnR, CD63, or transmission electron microscope.
For the quantitation of LAM uptake, two nearly confluent mono-HLA-DR, the CD1b molecules were detected with an unconjugated
mouse anti-CD1b antibody (4A7.6). The mouse Fc region epitopes layers of APC were pulsed with LAM (10 mg/ml) for 3 hr. One mono-
layer was first incubated with a-mannan (Sigma Chemical Co.) at awere coated with a goat anti–mouse IgG Fab fragment at a concen-
tration of 2 mg/ml followed by rabbit anti–goat IgG Texas red– concentration of 200 mg/ml for 30 min prior to the addition of LAM.
After fixation, sectioning, and immunogold labeling for LAM andconjugated antibodies. After extensive washing, the cells were fi-
nally labeled with either anti-CD63-fluorescein isothiocyanate CD63, the amount of LAM that was internalized in the control and
a-mannan-treated APC was determined by counting LAM-specific(FITC), anti-CD71-FITC (anti-TfnR), or anti-HLA-DR-FITC (B8.12.2;
Immunotech, Westbrook, ME) for 90 min at room temperature. For immunogold particles that colocalized with CD63. In two indepen-
dent quantitation experiments, 20 cells from each group were ana-the colocalization of CD1b with MHC class I or a-adaptin, the cells
were incubated overnight at 48C with W6/32 or anti-a-adaptin (AP.6; lyzed. The number of gold particles per unit of cell area was deter-
mined by morphometric analysis.provided by Dr. F. Brodsky), respectively. After the above detection
scheme was applied, the final staining step was performed with The protocol for the quantitation of LAM transport to late endo-
somes in the presence and absence of the endosome acidificationWM25, an anti-CD1b-FITC antibody.
MR molecules were detected with a goat anti-MR antiserum (pro- inhibitor concanamycin A (Folimycin; Kamida Biomedical, Ventura,
CA) was similar to that described for the LAM uptake quantitation.vided by Dr. P. Stahl), which was used at a dilution of 1:300. The
MR proteins were fluorescently detected with a rabbit anti–goat IgG APC were incubated with 10 nM concanamycin A for 30 min prior
to the addition of LAM. We compared the amount of LAM thatTexas red–conjugated antibody. The MR was colocalized with the
TfnR, CD63, a-adaptin, or CD1b, which were detected with either colocalized with the late endosome/lysosome markers CD63 and
cathepsin D in the concanamycin A–treated and control cells byFITC-conjugated mouse monoclonal antibodies (TfnR and CD63)
or with unconjugated antibodies followed by rabbit anti–mouse immunoelectron microscopy. The number of these vesicles that
colocalized with CD63 or cathepsin D was determined. VesiclesIgG-FITC.
were scored as positive for either LAM or organelle-specific markers
only if there were three or more of the respective immunogold parti-Dextran Labeling of Endocytic Compartments
cles present. The number of vesicles that contained LAM and wereDextran labeling was performed by incubating adhered APC with
positive for CD63 or cathepsin D was divided by the total numberdextran–Texas red (Molecular Probes, Eugene, OR) at a concentra-
of LAM-containing vesicles in each case. For each marker, 100tion of 600 mg/ml for 15 min (to label early endosomes), 2 hr (to label
vesicles were counted; similar results were obtained from two inde-late endosomes), or for 1 hr, followed by an overnight incubation to
pendent labeling experiments.label mature endocytic structures such as lysosomes and MIICs.
The cells were washed in PBS and fixed in 4% formaldehyde. The
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APC as described above. MR and CD1b were detected with rabbit
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